レボフロクサシンの薬物動力学:初期の臨床試験のための新しいパラダイム
S L Preston1, G L Drusano, A L Berman
1Department of Medicine, Albany Medical College, NY 12208, USA.
JAMA
|January 24, 1998
まとめ
この研究では,病原体のピークレボフロクサシン血濃度と最小抑制濃度 (MIC) の比が,治療の成功結果を有意に予測することを発見しました. 少なくとも12.2のピーク/MIC比は,最良の臨床的および微生物学的反応と関連していました.
科学分野:
- 薬理学 薬理学とは
- 感染症 感染症は感染症です.
- クリニック・トライアル 臨床試験
背景:
- 最適な抗生物質の投与量を確立することは,第3相臨床試験において極めて重要です.
- 薬物の暴露と病原体感受性 (MIC) を関連付けることは,投与量の選択を導くことができます.
- 早期の薬理学効果モデリングは,治療応答の最大化に役立ちます.
研究 の 目的:
- レボフロクサシンの血濃度と患者のアウトカムとの関係を定量化するために.
- レボフロクサシン曝露と有害事象の相関性を評価する.
- 適した臨床的および微生物学的結果を得るための最適な曝露の値を決定する.
主な方法:
- バクテリア感染の患者313人を対象とした多センター,オープンラベル試験です.
- 血濃度-時間データと病原体MICを分析した.
- ロジスティック回帰は,ピーク/MIC比率と結果の関連性をモデル化しました.
主要な成果:
- ピーク/MIC比率と感染部位は,臨床結果を予測した (P<.001).
- ピーク/MIC比は,微生物学的根絶を予測した (P<.001).
- 好ましい結果は,ピーク/MIC比率≥12.2.2で最も可能性が高かった.
結論:
- レボフロキサシンは,高い臨床 (95%) と微生物学的 (96%) 応答率を達成しました.
- 薬物曝露は,治療の成功と有意に結びついていた.
- 薬理学モデリングは,用量最適化を加速し,患者のアウトカムを改善することができます.
関連する概念動画
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Pharmacodynamics: Overview and Principles
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
Pharmacodynamic Models: Linear Concentration–Effect Model
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...


